NASDAQ:HTBX

Heat Biologics (HTBX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$2.38
$2.38
52-Week Range
N/A
Volume
43,600 shs
Average Volume
171,558 shs
Market Capitalization
$61.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HTBX stock logo

About Heat Biologics Stock (NASDAQ:HTBX)

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

HTBX Stock News Headlines

Scorpius Holdings Inc (SCPX)
What Wall Street expects from Heat Biologics's earnings
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Reducing heat transfers – houses
How extreme heat may wreak havoc on your flight
The heat index explained in...90 seconds
See More Headlines
Receive HTBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heat Biologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:HTBX
Fax
N/A
Employees
49
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$61.05 million
Optionable
Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Jeffrey Alan Wolf J.D. (Age 59)
    Founder, Chairman, CEO & Pres
    Comp: $1.31M
  • Mr. William L. Ostrander (Age 54)
    CFO & Sec.
    Comp: $371.07k
  • Dr. Justin Stebbing FRCP
    FRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr.
    F.A.C.S., FACS, M.D., Chief Medical Advisor
  • Dr. Anthony M. Manning Ph.D. (Age 60)
    Chief Scientific Advisor
  • Dr. Paul W. Tebbey M.B.A.
    Ph.D., Sr. VP of Product Devel. & Portfolio Strategy

HTBX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Bionano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).

This page (NASDAQ:HTBX) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners